메뉴 건너뛰기




Volumn 31, Issue 2, 2013, Pages 469-472

Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma

Author keywords

Extranodal NK T cell lymphoma; Gemcitabine; Salvage

Indexed keywords

ASPARAGINASE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MEPREDNISONE; METHOTREXATE; OXALIPLATIN; PREDNISONE; VINCRISTINE;

EID: 84879549921     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9889-4     Document Type: Article
Times cited : (49)

References (22)
  • 1
    • 65449159015 scopus 로고    scopus 로고
    • Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: A study of 136 cases from the International Peripheral T-Cell Lymphoma Project
    • 19029440 10.1182/blood-2008-10-185256 1:CAS:528:DC%2BD1MXlsVWrsLs%3D
    • Au WY, Weisenburger DD, Intragumtornchai T, et al. (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113:3931-3937
    • (2009) Blood , vol.113 , pp. 3931-3937
    • Au, W.Y.1    Weisenburger, D.D.2    Intragumtornchai, T.3
  • 2
    • 0035074460 scopus 로고    scopus 로고
    • CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?
    • 11332147 10.1023/A:1011144911781 1:STN:280:DC%2BD3MrhsFCjtQ%3D%3D
    • Kim WS, Song SY, Ahn YC, et al. (2001) CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349-352
    • (2001) Ann Oncol , vol.12 , pp. 349-352
    • Kim, W.S.1    Song, S.Y.2    Ahn, Y.C.3
  • 3
    • 33644843494 scopus 로고    scopus 로고
    • Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study
    • 16380410 10.1200/JCO.2005.04.1384
    • Lee J, Suh C, Park YH, et al. (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618
    • (2006) J Clin Oncol , vol.24 , pp. 612-618
    • Lee, J.1    Suh, C.2    Park, Y.H.3
  • 4
    • 77953227669 scopus 로고    scopus 로고
    • Prognostic factors for mature natural killer (NK) cell neoplasms: Aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
    • 19850638 10.1093/annonc/mdp418 1:STN:280:DC%2BC3c3ptFymtw%3D%3D
    • Suzuki R, Suzumiya J, Yamaguchi M, et al. (2010) Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21:1032-1040
    • (2010) Ann Oncol , vol.21 , pp. 1032-1040
    • Suzuki, R.1    Suzumiya, J.2    Yamaguchi, M.3
  • 5
    • 33645455419 scopus 로고    scopus 로고
    • The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma
    • Lee SH, Ahn YC, Kim WS, Ko YH, Kim K, Park K (2006) The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematol-Hematol J 91:427-428
    • (2006) Haematol-Hematol J , vol.91 , pp. 427-428
    • Lee, S.H.1    Ahn, Y.C.2    Kim, W.S.3    Ko, Y.H.4    Kim, K.5    Park, K.6
  • 6
    • 1842407749 scopus 로고    scopus 로고
    • CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance
    • 9108417 1:CAS:528:DyaK2sXisFChu7s%3D
    • Drenou B, Lamy T, Amiot L, et al. (1997) CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 89:2966-2974
    • (1997) Blood , vol.89 , pp. 2966-2974
    • Drenou, B.1    Lamy, T.2    Amiot, L.3
  • 7
    • 0028791591 scopus 로고
    • Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells
    • 8635042 10.1002/1097-0142(19951201)76:11<2351: AID- CNCR2820761125>3.0.CO;2-1 1:STN:280:DyaK283itlaqsw%3D%3D
    • Yamaguchi M, Kita K, Miwa H, et al. (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76:2351-2356
    • (1995) Cancer , vol.76 , pp. 2351-2356
    • Yamaguchi, M.1    Kita, K.2    Miwa, H.3
  • 8
    • 73349087528 scopus 로고    scopus 로고
    • Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study
    • 19884539 10.1200/JCO.2009.23.8592 1:CAS:528:DC%2BC3cXhtVWisLk%3D
    • Kim SJ, Kim K, Kim BS, et al. (2009) Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 27:6027-6032
    • (2009) J Clin Oncol , vol.27 , pp. 6027-6032
    • Kim, S.J.1    Kim, K.2    Kim, B.S.3
  • 9
    • 73949086783 scopus 로고    scopus 로고
    • Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211
    • 19805668 10.1200/JCO.2009.23.8295 1:CAS:528:DC%2BC3cXhtVWit7s%3D
    • Yamaguchi M, Tobinai K, Oguchi M, et al. (2009) Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27:5594-5600
    • (2009) J Clin Oncol , vol.27 , pp. 5594-5600
    • Yamaguchi, M.1    Tobinai, K.2    Oguchi, M.3
  • 10
    • 18044390875 scopus 로고    scopus 로고
    • Nasal-type NK/T cell lymphoma: Clinical features and treatment outcome
    • 15798768 10.1038/sj.bjc.6602502 1:STN:280:DC%2BD2M7nvVGrsg%3D%3D
    • Lee J, Kim WS, Park YH, et al. (2005) Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 92:1226-1230
    • (2005) Br J Cancer , vol.92 , pp. 1226-1230
    • Lee, J.1    Kim, W.S.2    Park, Y.H.3
  • 11
    • 84867130407 scopus 로고    scopus 로고
    • Extranodal natural killer/T-cell lymphoma from skin or soft tissue: Suggestion of treatment from multinational retrospective analysis
    • 22547542 10.1093/annonc/mds096 1:STN:280:DC%2BC38rptl2ntQ%3D%3D
    • Ahn HK, Suh C, Chuang SS, et al. (2012) Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis. Ann Oncol 23(10):2703-2707
    • (2012) Ann Oncol , vol.23 , Issue.10 , pp. 2703-2707
    • Ahn, H.K.1    Suh, C.2    Chuang, S.S.3
  • 12
    • 20444463408 scopus 로고    scopus 로고
    • Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy
    • 15963893 10.1016/j.ejca.2005.03.010
    • Lee J, Park YH, Kim WS, et al. (2005) Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 41:1402-1408
    • (2005) Eur J Cancer , vol.41 , pp. 1402-1408
    • Lee, J.1    Park, Y.H.2    Kim, W.S.3
  • 13
    • 56549093825 scopus 로고    scopus 로고
    • Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: A multinational, multicenter, matched controlled study
    • 19041057 10.1016/j.bbmt.2008.09.014
    • Lee J, Au WY, Park MJ, et al. (2008) Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 14:1356-1364
    • (2008) Biol Blood Marrow Transplant , vol.14 , pp. 1356-1364
    • Lee, J.1    Au, W.Y.2    Park, M.J.3
  • 14
    • 81755172136 scopus 로고    scopus 로고
    • Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group study
    • 21990393 10.1200/JCO.2011.35.6287 1:CAS:528:DC%2BC38Xns1Sgsw%3D%3D
    • Yamaguchi M, Kwong YL, Kim WS, et al. (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410-4416
    • (2011) J Clin Oncol , vol.29 , pp. 4410-4416
    • Yamaguchi, M.1    Kwong, Y.L.2    Kim, W.S.3
  • 15
    • 79951483189 scopus 로고    scopus 로고
    • Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
    • 21123825 10.1182/blood-2010-09-307454 1:CAS:528:DC%2BC3MXisFKqs7s%3D
    • Jaccard A, Gachard N, Marin B, et al. (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117:1834-1839
    • (2011) Blood , vol.117 , pp. 1834-1839
    • Jaccard, A.1    Gachard, N.2    Marin, B.3
  • 16
    • 77951964918 scopus 로고    scopus 로고
    • Gemcitabine as single agent in pretreated T-cell lymphoma patients: Evaluation of the long-term outcome
    • 19887465 10.1093/annonc/mdp508 1:STN:280:DC%2BC3c3htFKnsA%3D%3D
    • Zinzani PL, Venturini F, Stefoni V, et al. (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21:860-863
    • (2010) Ann Oncol , vol.21 , pp. 860-863
    • Zinzani, P.L.1    Venturini, F.2    Stefoni, V.3
  • 17
    • 27244449294 scopus 로고    scopus 로고
    • Selective apoptosis of natural killer-cell tumours by l-asparaginase
    • 16156856 10.1111/j.1365-2141.2005.05694.x 1:CAS:528:DC%2BD2MXhtFegtLzF
    • Ando M, Sugimoto K, Kitoh T, et al. (2005) Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130:860-868
    • (2005) Br J Haematol , vol.130 , pp. 860-868
    • Ando, M.1    Sugimoto, K.2    Kitoh, T.3
  • 18
    • 34547842304 scopus 로고    scopus 로고
    • Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: Nuclear factor-kappa B pathway as a potential therapeutic target
    • 17627615 10.1111/j.1349-7006.2007.00549.x 1:CAS:528:DC%2BD2sXhtVaksrzF
    • Chuang HC, Lay JD, Hsieh WC, Su IJ (2007) Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: nuclear factor-kappa B pathway as a potential therapeutic target. Cancer Sci 98:1281-1287
    • (2007) Cancer Sci , vol.98 , pp. 1281-1287
    • Chuang, H.C.1    Lay, J.D.2    Hsieh, W.C.3    Su, I.J.4
  • 19
    • 79551696483 scopus 로고    scopus 로고
    • Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling
    • 21294123 10.1002/path.2823 1:CAS:528:DC%2BC3MXkt1Siu7Y%3D
    • Ng SB, Selvarajan V, Huang G, et al. (2011) Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 223:496-510
    • (2011) J Pathol , vol.223 , pp. 496-510
    • Ng, S.B.1    Selvarajan, V.2    Huang, G.3
  • 20
    • 56749102974 scopus 로고    scopus 로고
    • Phase i study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
    • 18689866 10.1093/annonc/mdn431 1:STN:280:DC%2BD1cjlsFGiug%3D%3D
    • Lee J, Suh C, Kang HJ, et al. (2008) Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 19:2079-2083
    • (2008) Ann Oncol , vol.19 , pp. 2079-2083
    • Lee, J.1    Suh, C.2    Kang, H.J.3
  • 21
    • 84856555122 scopus 로고    scopus 로고
    • Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: Analysis of efficacy and toxicity
    • 20734108 10.1007/s10637-010-9523-2 1:CAS:528:DC%2BC38XotVWiug%3D%3D
    • Kim SJ, Kim K, Park Y, et al. (2012) Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. Invest New Drugs 30:368-375
    • (2012) Invest New Drugs , vol.30 , pp. 368-375
    • Kim, S.J.1    Kim, K.2    Park, Y.3
  • 22
    • 0033934870 scopus 로고    scopus 로고
    • Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients
    • 10893292 1:CAS:528:DC%2BD3cXltlKqt7s%3D
    • Zinzani PL, Baliva G, Magagnoli M, et al. (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603-2606
    • (2000) J Clin Oncol , vol.18 , pp. 2603-2606
    • Zinzani, P.L.1    Baliva, G.2    Magagnoli, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.